Beam Therapeutics Inc.
General ticker "BEAM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.8B (TTM average)
Beam Therapeutics Inc. follows the US Stock Market performance with the rate: 51.8%.
Estimated limits based on current volatility of 3.6%: low 25.97$, high 27.89$
Factors to consider:
- Total employees count: 483 (+10.8%) as of 2024
- Top business risk factors: Insufficient funding, Market competition, Strategic risks and growth management, Regulatory and compliance, Labor/talent shortage/retention
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [19.28$, 38.70$]
- 2026-12-31 to 2027-12-31 estimated range: [16.86$, 34.96$]
Financial Metrics affecting the BEAM estimates:
- Negative: with PPE of -8.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -12.76 <= 0.01
- Positive: -14.22 < Investing cash flow per share per price, % of -4.49
- Positive: Interest expense per share per price, % of 1.62 <= 3.28
- Negative: Industry earnings per price (median), % of -14.30 <= 0
- Positive: Shareholder equity ratio, % of 83.61 > 64.29
Short-term BEAM quotes
Long-term BEAM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $377.71MM | $63.52MM | $139.74MM |
| Operating Expenses | $554.19MM | $479.09MM | $523.44MM |
| Operating Income | $-176.49MM | $-415.57MM | $-383.69MM |
| Non-Operating Income | $45.32MM | $38.87MM | $303.70MM |
| Interest Expense | $0.00MM | $0.00MM | $43.73MM |
| R&D Expense | $437.38MM | $367.56MM | $409.62MM |
| Income(Loss) | $-131.16MM | $-376.70MM | $-79.99MM |
| Taxes | $1.37MM | $0.04MM | $0.00MM |
| Profit(Loss)* | $-132.53MM | $-376.74MM | $-79.99MM |
| Stockholders Equity | $981.33MM | $733.54MM | $1,238.36MM |
| Assets | $1,459.71MM | $1,103.82MM | $1,481.18MM |
| Operating Cash Flow | $-149.19MM | $-347.25MM | $-345.10MM |
| Capital expenditure | $33.73MM | $8.95MM | $14.95MM |
| Investing Cash Flow | $71.84MM | $185.01MM | $-121.44MM |
| Financing Cash Flow | $276.45MM | $7.74MM | $478.05MM |
| Earnings Per Share** | $-1.72 | $-4.58 | $-0.81 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.